

Initial Date: 07/19/2023

Revised Date:

Section: 9-39R

## ***Pralidoxime***

**Pharmacological Category:** Cholinesterase reactivator

**Routes:** IV/IM

**Indications:**

1. Exposure to organophosphate or nerve agents

**Expected effects:**

1. Decrease in symptoms

**Side effects:**

1. Blurred vision
2. Headache
3. Dizziness
4. Nausea

**Notes:**

1. This medication may be part of a Nerve Agent (NA) Antidote kit.
2. When not part of an NA kit, 600 mg pralidoxime (along with 2 mg Atropine) will be administered in place of each NA kit that was to be administered.

**Dosing: NERVE AGENT/ORGANOPHOSPHATE PESTICED ESPOSURE**

Indication: Symptomatic nerve agent or organophosphate pesticide exposure when a NA Antidote Kt is not available.

Adults and Pediatrics administer:



1. Pralidoxime 600 mg IV/IM for every one (1) NA Kit as required on Chart below.

**Michigan**  
**MEDICATION SECTION**  
**PRALIDOXIME**

Initial Date: 07/19/2023

Revised Date:

Section: 9-39R


	<b>Clinical Findings</b>	<b>Signs/Symptoms</b>	<b>Required Conditions</b>	<b>NA Kits To Be Delivered</b>
<b>SELF-RESCUE</b>	<b>Threshold Symptoms</b>	<ul style="list-style-type: none"> <li>• Dim vision</li> <li>• Increased tearing</li> <li>• Runny nose</li> <li>• Nausea/vomiting</li> <li>• Abdominal cramps</li> <li>• Shortness of breath</li> </ul>	Threshold Symptoms -and- Positive evidence of nerve agent or OPP on site  Medical Control Order	1 NA Kit (self-rescue)
<b>ADULT PATIENT &gt; 8 years of age</b>	<b>Mild Symptoms and Signs</b>	<ul style="list-style-type: none"> <li>• Increased tearing</li> <li>• Increased salivation</li> <li>• Dim Vision</li> <li>• Runny nose</li> <li>• Sweating</li> <li>• Nausea/vomiting</li> <li>• Abdominal cramps</li> <li>• Diarrhea</li> </ul>	 Medical Control Order	1 NA Kit
	<b>Moderate Symptoms and Signs</b>	<ul style="list-style-type: none"> <li>• Constricted pupils</li> <li>• Difficulty breathing</li> <li>• Severe vomiting</li> </ul>	Constricted Pupils	2 NA Kits
	<b>Severe Signs</b>	<ul style="list-style-type: none"> <li>• Constricted pupils</li> <li>• Unconsciousness</li> <li>• Seizures</li> <li>• Severe difficulty breathing</li> </ul>	Constricted Pupils	3 NA Kits (If 3 NA Kits are used, administer 1 <sup>st</sup> dose of available benzodiazepine)

**Michigan**  
**MEDICATION SECTION**  
**PRALIDOXIME**

Initial Date: 07/19/2023

Revised Date:

Section: 9-39R

<b>PEDIATRIC &lt; 8 years of age</b>	<b>Pediatric Patient with Non-Severe Signs/Symptoms</b>	<ul style="list-style-type: none"> <li>Mild or moderate symptoms as above</li> </ul>	<p>Threshold Symptoms -and- Positive evidence of nerve agent or OPP on site</p> <p> Medical Control Order</p>	1 NA Kit
	<b>Pediatric Patient with Severe Signs/Symptoms</b>	<ul style="list-style-type: none"> <li>Constricted pupils</li> <li>Unconsciousness</li> <li>Seizures</li> <li>Severe difficulty breathing</li> </ul>	<p>Severe breathing difficulty</p> <p>Weakness</p>	1 NA Kit

Used in the Following Protocols

Nerve Agent/Organophosphate Pesticide Exposure (Section 10 Special Operations)